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The Babesia bovis merozoite surface antigen 1 (MSA-1) is an immunodominant membrane glycoprotein that
is the target of invasion-blocking antibodies. While antigenic variation has been demonstrated in MSA-1
among strains from distinct geographical areas, the extent of sequence variation within a region where it is
endemic and the effect of variation on immunologic cross-reactivity have not been assessed. In this study,
sequencing of MSA-1 from two Australian B. bovis vaccine strains and 14 breakthrough isolates from vacci-
nated animals demonstrated low sequence identity in the extracellular region of the molecule, ranging from
19.8 to 46.7% between the T vaccine strain and eight T vaccine breakthrough isolates, and from 18.7 to 99%
between the K vaccine strain and six K vaccine breakthrough isolates. Although MSA-1 amino acid sequence
varied substantially among strains, overall predicted regions of hydrophilicity and hydrophobicity in the
extracellular domain were conserved in all strains examined, suggesting a conserved functional role for MSA-1
despite sequence polymorphism. Importantly, the antigenic variation created by sequence differences resulted
in a lack of immunologic cross-reactivity among outbreak strains using sera from animals infected with the B.
bovis vaccine strains. Additionally, sera from cattle hyperinfected with the Mexico strain of B. bovis and shown
to be clinically immune did not cross-react with MSA-1 from any other isolate tested. The results indicate that
isolates of B. bovis capable of evading vaccine-induced immunity contain an msa-1 gene that is significantly
different from the msa-1 of the vaccine strain, and that the difference can result in a complete lack of
cross-reactivity between MSA-1 from vaccine and breakthrough strains in immunized animals.
Parasites in the genus Babesia are tick-borne, apicomplexan
hemoparasites that cause severe hemolytic anemia, abortion,
cerebral babesiosis, and death in susceptible animals. Vaccines
directing the immune response against proteins involved in
erythrocyte invasion, including merozoite surface proteins,
provide a potential control point that targets the extracellular
merozoite stage (4–7, 22). However, antigenic variation poses
a challenge to the use of surface antigens in vaccines (14, 19,
23, 25).
Babesia bovis merozoite surface antigen 1 (MSA-1) and
MSA-2 are part of the variable merozoite surface antigen fam-
ily (10, 15). These proteins are exposed to the host immune
system and have immunodominant CD4 T lymphocyte
epitopes (4, 26). Monospecific antiserum directed against
MSA-1 and MSA-2 is able to block entry of the merozoite into
the erythrocyte in vitro (15, 21). However, antigenic polymor-
phism of variable merozoite surface antigen proteins among
strains is a general feature. It is clear that enough differences
exist among geographically diverse strains to translate into a
complete lack of immunologic cross-reactivity using monoclo-
nal antibodies and postinfection immune sera (14, 19, 23, 25).
Limited sequence information is available for MSA-1, and
all sequences obtained to date have been derived from strains
isolated in distinct geographic areas (27). As a family, variable
merozoite surface antigen genes (vmsa) share sequence iden-
tity or significant similarity in the 5 and 3 signal sequence
regions, and in short stretches outside of these regions. Probes
based on the 5 and 3 signal sequences hybridize in Southern
blots to all members of the variable merozoite surface antigen
family. However, cross-hybridization between alleles does not
occur when sequences outside the 5 and 3 regions are used as
a probe (15). The extent of the sequence variation among B.
bovis isolates within an endemic area has not been examined.
Whether MSA-1 sequences vary among strains from region
where it is endemics to the same degree as among strains from
distinct geographic regions, or whether MSA-1 sequences are
more stable among strains from regions where it is endemic is
unknown.
This study was designed to examine the extent of MSA-1
sequence diversity in a biologically and immunologically rele-
vant system using live attenuated vaccine strains from Austra-
lia, and organisms isolated from vaccinated cattle that subse-
quently developed clinical babesiosis (termed breakthrough or
outbreak isolates). The breakthrough isolates have been char-
acterized using genotypic markers and have been shown to be
genetically different from the vaccine strain (18). While geno-
typic differences have been identified among these strains and
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isolates, the variation in specific genes that may be targets for
protective immunity, such as MSA-1 and MSA-2, has not been
determined. The hypotheses that breakthrough isolates reflect
the same degree of sequence diversity as geographic strains
and that the sequence diversity results in a lack of immunologic
cross-reactivity among the vaccine strains and breakthrough
isolates were tested. To test these hypotheses, we examined the
extent of MSA-1 sequence diversity among a large number of
vaccine strains and breakthrough isolates and determined the
effect of the MSA-1 sequence variation on immunologic cross-
reactivity.
MATERIALS AND METHODS
Origin of B. bovis strains and isolates. The Mo7 biological clone of B. bovis
was derived from the Mexico strain by limiting dilution as described (13, 24) and
maintained as a cryopreserved stabilate in liquid nitrogen. Parasites were grown
in long-term microaerophilic stationary-phase culture by previously described
techniques (17). Attenuated B. bovis K and T strains were attained by serial
passage through splenectomized calves as previously described (2, 3). Vaccine
breakthrough isolates were obtained from cattle vaccinated with the T or K
strains that subsequently were diagnosed with clinical babesiosis. The isolates
were then passaged once through splenectomized calves as described previously
(2). Outbreak isolates from animals immunized with the T vaccine were desig-
nated as G isolates (n  8), and those from animals immunized with the K
vaccine as E and F isolates (n  6) (2, 3).
Generation of postinfection sera. Calves were hyperinfected with the Mexico
strain of B. bovis as previously described (13). Briefly, three 4- to 5-month-old
Holstein steers were infected by intravenous subinoculation of 5  107 infected
red blood cells from a splenectomized calf. The cattle were then challenged three
more times intravenously with 108 infected red blood cells once by subinocula-
tion, and twice using culture-derived parasites. Two weeks after the fourth
inoculation, the calves were bled and the serum was used in subsequent immu-
noblots as described previously (9). Sera were also obtained from animals inoc-
ulated with stabilate of the T or K vaccine strains or with blood from an animal
experimentally infected with G06 stabilate. Postinfection sera from hyper-in-
fected cattle as well as cattle infected once with the T or K vaccine strain, or the
G06 outbreak strain were analyzed for reactivity against homologous recombi-
nant protein and cross-reactivity against heterologous recombinant protein by
immunoblot essentially as described (9, 20).
Sequencing of msa-1 from vaccine strains and breakthrough isolates. Genomic
DNA from B. bovis T and K vaccine strains, and the E86, F3, F28, F35, F40, F64
(K vaccine breakthroughs), G06, G19, G36, G42, G45, G52, G56, and G51 (T
vaccine breakthroughs) isolates was used, prepared as previously described by
Lew (18). Genomic DNA was suspended in 0.01 M Tris, pH 7.5, and approxi-
mately 25 ng was used for PCR. The oligonucleotide primers used to clone msa-1
from the K, T, E86, F28, F35, F40, F3, F64, G06, G19, G36, G42, and G52
isolates were MSA1 pro (5-AGAGTGCGTGTGTGCATATAATTC-3) and
MSA1 rev2 (5-TAGCCACAGTCAATCCGCC-3). The primers used to clone
msa-1 from the G45, G51, and G56 isolates were MSA1 5 flank (5-GGGAA
ACACATTCACTGTACAAGC-3), MSA-1 3 flank (5-GATGACTATGTCA
TTGCCGCTG-3), and MSA1 rev2. The fragments were cloned into the p0Blunt
or pCR4 TOPO cloning vector (Invitrogen). Plasmid DNA was prepared using
the Roche High Prime Kit and was sequenced using ABI chemistries. The
sequences were assembled and analyzed with the Vector Suite NTI (InforMax).
Phylogenetic analysis was performed with PHYLIP (Phylogeny Inference
Package, http://evolution.genetics.washington.edu/phylip.html [8]). TMpred (http:
//www.ch.embnet.org/software/TMPRED_form.html) was used to predict secondary
structure and hydrophilicity. NNpredict (http://cmpharm.ucsf.edu/cgi-bin
/nnpredict.pl) was used to predict tertiary structure and the Vector Suite NTI was
used to predict antigenicity.
Expression of recombinant proteins. The MSA-1 extracytoplasmic regions of
strains Mo7, T, K, G45, G06, G36, F35, and G52 were amplified from sequencing
vectors by PCR using primers that lie inside the conserved 5 and 3 regions
(Table 1). Amplicons were cloned into the pTrcHis expression vector using the
pTricHis TOPO TA cloning kit (Invitrogen) for expression of rMSA-1. The
primers were designed to allow in-frame cloning into the vector. For expression
of recombinant protein, a single Escherichia coli colony was inoculated into 10 ml
of Luria broth containing 50 g of carbenicillin per ml and incubated overnight
at 37°C with shaking. Three ml of the culture was subinoculated into 100 ml
Luria broth with 50 g/ml carbenicillin and incubated at 37°C for 3 h with
shaking. Production of recombinant protein was induced with 1 mM isopropyl-
thiogalactopyranoside (IPTG) and cells were incubated an additional 4 h at 37°C.
The cells were pelleted and the pellet was frozen at 20°C overnight. The pellet
was thawed and resuspended in 4 ml binding buffer (500 mM NaCl, 20 mM
K2HPO4, 20 mM KH2PO4, pH 7.8) and sonicated to lyse the cells. Recombinant
protein was purified on a Ni2 column using ProBond resin (Invitrogen), eluted
in 1.5 ml fractions with elution buffer (500 mM NaCl, 20 mM K2HPO4, 20 mM
KH2PO4, pH 4) into 75 l 1 M Tris, pH 8, and quantified using a microbicin-
choninic acid protein reagent kit (Pierce). Relative purity of the antigen was
confirmed in Coomassie blue-stained sodium dodecyl sulfate-polyacrylamide
gels.
Nucleotide sequence accession numbers. These sequences were submitted to
GenBank under accession numbers DQ028735 to DQ028747. AF275908: Babe-
sia bovis, clone of Mexico Mo7 strain, merozoite surface antigen-1 cDNA se-
quence. AF275909: Babesia bovis, Argentina S2P strain, merozoite surface anti-
gen-1 cDNA sequence. AF275910: Babesia bovis, Argentina R1A strain,
merozoite surface antigen-1 cDNA sequence. DQ028735: Babesia bovis, Austra-
lia T vaccine strain, merozoite surface antigen-1 genomic sequence. DQ028736:
Babesia bovis, Australia K vaccine strain, merozoite surface antigen-1 genomic
sequence. DQ028737: Babesia bovis, Australia G19 outbreak isolate, merozoite
surface antigen-1 genomic sequence. DQ028738: Babesia bovis, Australia F64
outbreak isolate, merozoite surface antigen-1 genomic sequence. DQ028739:
Babesia bovis, Australia E86 outbreak isolate, merozoite surface antigen-1
genomic sequence. DQ028740: Babesia bovis, Australia F35 outbreak isolate,
merozoite surface antigen-1 genomic sequence. DQ028741: Babesia bovis, Aus-
tralia G06 outbreak isolate, merozoite surface antigen-1 genomic sequence.
DQ028742: Babesia bovis, Australia G52 outbreak isolate, merozoite surface
antigen-1 genomic sequence. DQ028743: Babesia bovis, Australia F28 outbreak
isolate, merozoite surface antigen-1 genomic sequence. DQ028744: Babesia bo-
vis, Australia F40 outbreak isolate, merozoite surface antigen-1 genomic se-
quence. Q028745: Babesia bovis, Australia G36 outbreak isolate, merozoite sur-
face antigen-1 genomic sequence. DQ028746: Babesia bovis, Australia G51
outbreak isolate, merozoite surface antigen-1 genomic sequence. DQ028747:
Babesia bovis, Australia G45 outbreak isolate, merozoite surface antigen-1
genomic sequence.
RESULTS
Comparative analyis of MSA-1 sequence and predicted
structure. Limited sequence information is available for
MSA-1 and has been obtained only among strains from distinct
geographic areas (27). The extent of sequence diversity within
an region where it is endemic has not been examined. In
addition, while genotypic differences have been identified be-
tween vaccine strains and breakthrough isolates, it is unknown
whether MSA-1 from the breakthrough isolates varies from
vaccine strains. To address these questions, the msa-1 gene
TABLE 1. Oligonucleotides used for amplification of msa-1 genes
for expression of the extracellular domain
Primer Sequence
Mo7-5...................5-GCCGATACTTCAATCGTCCTTCC-3
Mo7-3...................5-ATGTACCCTGTTGTCCTTGGAGG-3
T-5 ........................5-ATTAATCCTCCATCCGATGCTCC-3
T-3 ........................5-ATTGTCCATGAGGTTACTTGTAGATTG-3
K-5........................5-GTCGATTCTTCACCCGATGCTCC-3
K-3........................5-ACTGACCATTGAGGTTTCCTGTAG-3
G06-5 ...................5-CCTGCTTATGTACCTGTTGCTTC-3
G06-3 ...................5-AGCCATTGAGGTTTCCCTGCAGG-3
G36-5 ...................5-ATTGATACTTCATCGCCTCTTCC-3
G36-3 ...................5-ATTGTCCATTGAGGTTACCTTCAGG-3
G45-5 ...................5-CCTGCTTATCTACCTGTTGCAAC-3
G45-3 ...................5-AAGAACCATCGGGTTTTTGGAGG-3
G52-5 ...................5-GTCGATTCTTCATCCGATCTTCC
G52-3 ...................5-ATGGTCCACTGAGGTTTCCTG-3
F35-5 ....................5-GTTAGGATTATTAATCC-3
F35-3 ....................5-GGTTTCTTGTTGGGGTTGTC-3
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from two Australian vaccine strains, designated K and T (2),
and multiple breakthrough isolates were cloned and se-
quenced. E and F outbreak isolates (E86, F28, F35, F40, F3,
and F64) were obtained from cattle immunized with the K
strain (2), and G outbreak isolates (G06, G19, G36, G42, G45,
G51, G56, and G52) were obtained from cattle immunized
with the T strain (3).
The deduced amino acid sequences of the MSA-1 extracel-
lular domain among all isolates in this region of endemicity in
Australia vary extensively, ranging from only 17% sequence
identity between the G51 and G64 isolates to 99% sequence
identity between the G19 and F64 isolates. When vaccine
strains are compared directly to the associated outbreak iso-
lates, sequence identity ranged from 19.8 to 46.7% between the
T vaccine strain and the eight T breakthrough isolates, and
from 18.7 to 99% between the K vaccine strain and the six K
breakthrough isolates. Additionally, a phylogenetic analysis of
all MSA-1 sequences (PHYLIP, http://evolution.genetics.wash-
ington.edu/phylip.html [8]) indicates that all sequences cluster
into three to four major groups and MSA-1 from the vaccine
breakthrough isolates, with one exception (F40), are in distinct
branches from their respective vaccine strain (Fig. 2). The F40
MSA-1 sequence shares 99% identity with the K vaccine strain.
Interestingly, some of the Australia MSA-1 sequences are
more closely related to the Mo7 cloned laboratory strain or
Argentina R1A and S2P strains than to other Australia isolates
(Fig. 1 and 2).
The majority of strictly conserved amino acids are in the
amino terminal and carboxy terminal signal sequence regions,
as previously demonstrated (15). In the amino terminal leader
sequence, 3 of 21 amino acids are strictly conserved, while in all
strains and isolates except G51, six of nine amino acids in the
carboxy-terminal glycerylphosphatidylinositol signal sequence
are strictly conserved (Fig. 1). Throughout the rest of the
molecule, only single amino acids or small clusters of amino
acids are conserved in all isolates, including a strictly conserved
YFK motif at amino acids 174 to 176 (Fig. 1). The last strictly
conserved amino acid in the extracellular domain is at position
205, and there is significantly more variation in the carboxy
terminus (approximately 100 amino acids) of the molecule.
Even though overall sequence conservation is relatively low
among different strains and isolates, predictive algorithms
(TMpred and NNpredict) suggest that the molecules have a
similar membrane structure. Six representative analyses are
shown in Fig. 3. Each MSA-1 has a predicted amino and
carboxy terminal hydrophobic domain, and similarly located
-helices, -pleated sheets (data not shown), and hydrophilic
peaks within the extracytoplasmic region. All strains contain a
major hydrophilic peak that corresponds approximately to
amino acids 130 to 180, and contains the strictly conserved
YFK motif. Additionally, most strains and isolates contain two
to three additional, often similarly located, hydrophilic peaks
between amino acids 30 to 130 and 180 to 280 (Fig. 3).
Antigenic cross-reactivity among B. bovis strains – postin-
fection sera. Previous studies suggest that there is a complete
lack of MSA-1 cross-reactivity among strains from distinct geo-
graphic areas (14, 23, 25). The availability of postinfection sera
against the Australia vaccine strains allowed us to determine
whether the sequence diversity in breakthrough isolates also
resulted in a lack of cross-reactivity. Recombinant his-tagged
MSA-1 from the Mo7 laboratory strain, the T and K vaccine
strains, and the G06, G45, G36, G52, and F35 breakthrough
isolates were used for these experiments. Postinfection serum
against the T vaccine strain and the T vaccine outbreak isolate
G06 only reacted with homologous MSA-1 antigen (Fig. 4A
and B). Antiserum against the K vaccine strain reacted with
rMSA-1 from both the K strain and G45 isolate, a T vaccine
outbreak isolate (Fig. 4C). Interestingly, the G45 isolate
FIG. 2. Dendrogram of MSA1 sequences from various B. bovis
strains, including Australian vaccine strains and outbreak isolates. Mo7
is the biological clone of a Mexico isolate; R1A and S2P are Argentina
strains; T and K strains are Australian vaccine strains; G isolates are T
vaccine breakthrough isolates; and E and F are K vaccine break-
through isolates.
FIG. 1. Sequence alignments of MSA1 from selected B. bovis strains and isolates. Strictly conserved amino acids are in yellow boxes, partially
conserved amino acids are in blue and green. Mo7 is the biological clone of the Mexico strain; the T and K strains are Australia vaccine strains;
G isolates are T vaccine breakthroughs; F isolates are K vaccine breakthroughs. R1A and S2P are Argentina strains. Mo7, R1A, and S2P have been
previously published (27).
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MSA-1 is more distantly related to the K vaccine strain than
G52 (Fig. 2) to which there was no cross-reactivity with K
vaccine specific antiserum.
The ability to induce more extensive cross-reactivity after
multiple infections with the same strain was examined. Immu-
noblot analysis was performed using serum from three differ-
ent cattle (only data from one animal shown), each infected
four times with the B. bovis Mexico strain (13) and demon-
strated to be immune to challenge. The sera were used as a
probe against recombinant protein from the homologous Mo7
FIG. 3. Predicted membrane structure of MSA1 from T and K vaccine strains, and G36, F28, G52, and F64 breakthrough isolates. The
predicted membrane orientation was calculated with TMpred and is plotted on the y axis against the amino acid position on the x axis. The solid
line, i3o, is the calculation performed from N terminus to C terminus. The dashed line, o3i, is calculated from C terminus to N terminus.
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strain and heterologous Australia strains and isolates. The
results demonstrated strong reactivity of the hyper-infection
sera with homologous rMSA-1 from the Mo7 strain (Fig. 4D).
However, no reactivity with heterologous protein could be
detected, suggesting that multiple exposures to homologous
MSA-1 during vaccination or natural infection do not result in
development of antibody against B-lymphocyte epitopes
shared with heterologous MSA-1.
DISCUSSION
In this study, the sequence variation of B. bovis MSA-1
within an endemic area in a biologically relevant system of
vaccine strains and vaccine breakthrough isolates were exam-
ined. Since escape from clinical immunity almost certainly in-
volves variation in multiple genes and gene products, some of
which vary quite rapidly (1), we postulated that MSA-1 would
vary in at least some, but probably not all, of the breakthrough
isolates. However, extensive MSA-1 sequence variation was
detected between the attenuated strains used as modified live
vaccines in Australia, and, with one exception, every isolate
from vaccinated animals that were subsequently diagnosed
with clinical babesiosis. Since MSA-1 is encoded by a single
copy gene, it was somewhat surprising that the MSA-1 se-
quences varied so extensively, and that they varied in all but
one breakthrough isolate. Similar, but less extensive variation
has been seen in the single copy surface protein genes of other
apicomplexan hemoparasites, including the merozoite surface
proteins of Plasmodium falciparum (28), the major merozoite-
piroplasm surface antigen (Tams1) of Theileria annulata, and
the polymorphic immunodominant molecule (PIM) of Theile-
ria parva (11, 12). Genetic exchange is postulated to be the
major means of generating polymorphism in these single copy
genes, and in MSA-1, and most likely arises during diploid or
polyploid stages in the respective vectors (11, 12). No obvious
sites of recombination could be identified among the MSA-1
sequences derived in this study, unlike the related MSA-2
genes in which a conserved site of recombination has been
found (10).
Alignment of amino acid sequences of MSA-1 from these
strains as well as from laboratory and previously published
strains demonstrated that the majority of strictly conserved
amino acids were located in the N terminal and C terminal
signal sequences, as previously found (15), with only short
stretches of strictly or partially conserved amino acids in the
extracellular, hydrophilic domains. Despite limited sequence
conservation, however, analysis of the proteins from all strains
demonstrated a predicted conserved membrane orientation
and hydrophilic peak location, suggesting a conserved function
for the protein. The region that corresponds to the most hy-
drophilic domain contains a YFK motif that is strictly con-
served in all MSA-1 sequences from all strains and isolates
evaluated. The strict conservation of this tripeptide, as well as
the nine additional individual amino acids in the extracytoplas-
mic domain that are strictly conserved, suggests that they may
be essential for correct structure and function of the protein.
The Tams1 polypeptide of Theileria annulata contains a strictly
conserved KEK motif, as well as other conserved K residues
(16). Lysine is thought to be involved in intra- and intermo-
lecular cross-linking, and may be involved in erythrocyte bind-
ing. Of the other strictly conserved amino acids, 9/12 are in
predicted antigenic regions (data not shown), suggesting they
may contribute to epitopes that can induce cross-reactive an-
tibody.
A dendrogram generated using all known MSA-1 sequences
demonstrated that, with one exception (F40 and K vaccine),
each outbreak isolate was in a separate branch from its asso-
ciated vaccine strain. Interestingly, previous studies have dem-
onstrated similarities between F40 and K, including the ability
of the K vaccine to protect against F40 challenge (2, 18), and
suggested that F40 may not truly represent a breakthrough
isolate. All other isolates in this and previous studies have been
capable of overcoming vaccine-induced immunity in challenge
trials (2, 18).
Selection for MSA-1 diversity could be driven by immune
pressure, by a separate biological process, or both. The overall
population structure of MSA-1 is unknown in this endemic
area. It is possible that the sequence differences are simply a
result of random sampling in a markedly divergent population.
However, since all but one of the MSA-1 sequences from
breakthrough isolates were different from the vaccine strain,
and immune sera from cattle infected with a vaccine strain did
not cross-react with recombinant MSA-1 protein from any of
the associated outbreak isolates evaluated, immune selection
of MSA-1 variants may be a significant factor in development
of vaccine breakthroughs. Interestingly, cross-reactivity could
FIG. 4. MSA-1 cross-reactivity of postinfection sera. Recombinant
MSA-1 from multiple strains and isolates (as noted) and from recom-
binant B. bovis heat shock protein 20 (HSP20) (as a negative control)
were probed with postinfection bovine serum from a calf infected once
with the G06 isolate (panel A), the T vaccine strain (panel B), or the
K vaccine strain (panel C). Panel D is an immunoblot of the same
antigens infected with the Mexico strain and challenged three times
with the homologous strain.
VOL. 73, 2005 BABESIA BOVIS MSA-1 VARIATION AND CROSS-REACTIVITY 5393
 o
n
 O
ctober 18, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
not be generated in postinfection serum even after infection
and three challenges (13). These data suggest that once a
response to particular MSA-1 B-lymphocyte epitopes is estab-
lished in an infected or vaccinated animal, hyperinfection re-
sults in an anamnestic response to the same epitopes but does
not induce a response to additional epitopes that are shared
with heterologous MSA-1.
The role of MSA-1 in the merozoite membrane, either as a
structural protein or as a critical part of the erythrocyte attach-
ment and invasion process is unknown. The ability of antibody
against MSA-1 to block erythrocyte invasion of both the mer-
ozoite and the sporozoite in vitro suggests a critical function in
host cell entry. In this region where it is endemic, there is
clearly selection for parasites that express allelic variants of
MSA-1. The lack of cross-reactivity observed using postinfec-
tion serum suggests that immune pressure may play a role in
selection of these parasites.
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